September 28, 2018
Altimmune Announces Pricing of $12 Million Underwritten Public Offering
Media
September 27, 2018
Targovax to Host Key Opinion Leader Symposium on Oncolytic Viruses in New York City, 11 October 2018
September 27, 2018
Targovax announces interim results from Phase I trial of ONCOS-102 in checkpoint inhibitor refractory melanoma
September 26, 2018
Vicore Pharma postpones publication of interim report
September 24, 2018
Altimmune Announces $4.9 million Registered Direct Offering of Common Stock
September 24, 2018
Altimmune Awarded $2.5 Million in Additional BARDA Funding to Support NasoShield™ Development
September 19, 2018
BONESUPPORT highlights significant strategic progress at Capital Market Days in Stockholm and London
September 18, 2018
Strongbridge Biopharma plc to Participate in Two Upcoming Healthcare Investor Conferences
September 18, 2018
First patient starts treatment with Ygalo® in Oncopeptides’ Phase II study BRIDGE in RRMM patients with renal impairment
September 18, 2018
Vicore publishes prospectus and new financial information contained in the prospectus
